Modified RNAi agents

Patent metadata

Field	Value
Publication number	US-9708607-B2
Application number	US-201314419211-A
Country	US
Kind code	B2
Filing date	Aug 2, 2013
Priority date	Aug 3, 2012
Publication date	Jul 18, 2017
Grant date	Jul 18, 2017

Abstract

One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more xylo modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

First claim

We claim:

1. A double-stranded RNAi agent capable of inhibiting the expression of a target gene, comprising a duplex comprising a sense strand and an antisense strand, each strand having 12 to 30 nucleotides, wherein the duplex comprises at least one xylo modified moiety represented by formula (A):

wherein:
Y is H, alkyl or internucleotide linkage;
X is halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted aminoalkyl, substituted or unsubstituted alkyl; and
B is a natural or non-natural nucleobase.

2. The double-stranded RNAi agent of claim 1 , wherein X is F or OMe.

3. A double-stranded RNAi agent of claim 1 , represented by formula (III):
sense: 5 ′n p -N a —(XXX) i —N b —YYY—N b —(ZZZ) j —N a - n q 3′

antisense: 3 ′n p ′-N a ′—(X′X′X′) k —N b ′—Y′Y′Y′—N b ′—(Z′Z′Z′) l —N a ′- n q ′5′  (III)

wherein:
j, k, and 1 are each independently 0 or 1;
p and q are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotideseach Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
each n p and n q independently represents an overhang nucleotide; and
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
wherein at least one of n, N, X, Y, or Z is a xylo modified of formula (A); and
wherein modifications on Nb is different than the modification on Y and modifications on Nb′ is different than the modification on Y′.

4. A double-stranded RNAi capable of inhibiting the expression of a target gene, comprising a duplex comprising a sense strand and an antisense strand, each strand having 12 to 30 nucleotides, wherein the duplex comprises at least one xylo-modified or 3′-modified moiety, wherein the duplex region is 27-30 nucleotide pairs in length.

5. A double-stranded RNAi agent capable of inhibiting the expression of a target gene, comprising a duplex comprising a sense strand and an antisense strand, each strand having 12 to 30 nucleotides, wherein the duplex comprises at least one xylo-modified or 3′-modified moiety, and wherein the duplex further comprises at least one ligand.

6. The double-stranded RNAi agent of claim 5 , wherein the ligand is a one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

7. The double-stranded RNAi agent of claim 6 , wherein the ligand is

8. The double-stranded RNAi agent of claim 5 , wherein the ligand is attached to the 3′ end of the sense strand.

9. A double-stranded RNAi agent capable of inhibiting the expression of a target gene, comprising a duplex comprising a sense strand and an antisense strand, each strand having 12 to 30 nucleotides, wherein the duplex comprises at least one xylo-modified or 3′-modified moiety, and wherein the duplex further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

10. The double-stranded RNAi agent of claim 1 , wherein the nucleotide at the 1 position of the 5′-end of the duplex in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT.

11. The double-stranded RNAi agent of claim 1 , wherein the base pair at the 1 position of the 5′-end of the duplex in the antisense strand is an AU base pair.

12. The double-stranded RNAi agent of claim 3 , wherein the Y nucleotides contain a 2′-fluoro modification.

13. The double-stranded RNAi agent of claim 3 wherein the Y′ nucleotides contain a 2′-O-methyl modification.

14. A pharmaceutical composition comprising the double-stranded RNAi agent of claim 1 alone or in combination with a pharmaceutically acceptable carrier or excipient.

15. A method for inhibiting the expression of a target gene comprising the step of administering the double-stranded RNAi agent of claim 1 , in an amount sufficient to inhibit expression of the target gene.

16. The method of claim 15 , wherein the double-stranded RNAi agent is administered through subcutaneous or intravenous administration.

17. The double-stranded RNAi agent of claim 3 , further comprising at least one phosphorothioate or methylphosphonate internucleotide linkage.

18. The double-stranded RNAi agent of claim 3 , wherein the nucleotide at the 1 position of the 5′-end of the duplex in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT.

19. The double-stranded RNAi agent of claim 3 , wherein the base pair at the 1 position of the 5′-end of the duplex in the antisense strand is an AU base pair.

20. The double-stranded RNAi agent of claim 4 , wherein the double-stranded RNAi agent is represented by formula (III):
sense: 5 ′n p -N a —(XXX) i —N b —YYY—N b —(ZZZ) j —N a - n q 3′

antisense: 3 ′n p ′-N a ′—(X′X′X′) k —N b ′—Y′Y′Y′—N b ′—(Z′Z′Z′) l —N a ′- n q ′5′  (III)

wherein:
j, k, and 1 are each independently 0 or 1;
p and q are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotideseach Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
each n p and n q independently represents an overhang nucleotide; and
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
wherein at least one of n, N, X, Y, or Z is a xylo modified of formula (A); and
wherein modifications on Nb is different than the modification on Y and modifications on Nb′ is different than the modification on Y′.

21. The double-stranded RNAi agent of claim 4 , wherein the nucleotide at the 1 position of the 5′-end of the duplex in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT.

22. The double-stranded RNAi agent of claim 4 , wherein the base pair at the 1 position of the 5′-end of the duplex in the antisense strand is an AU base pair.

23. The double-stranded RNAi agent of claim 5 , wherein the double-stranded RNAi agent is represented by formula (III):
sense: 5 ′n p -N a —(XXX) i —N b —YYY—N b —(ZZZ) j —N a - n q 3′

antisense: 3 ′n p ′-N a ′—(X′X′X′) k —N b ′—Y′Y′Y′—N b ′—(Z′Z′Z′) l —N a ′- n q ′5′  (III)

wherein:
j, k, and 1 are each independently 0 or 1;
p and q are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotideseach Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
each n p and n q independently represents an overhang nucleotide; and
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independe

Assignees

• Alnylam Pharmaceuticals Inc

Inventors

• Rajeev Kallanthottathil G
• Manoharan Muthiah

Classifications

• C12N2310/3521

  Methyl · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title

• C12N2310/31

  of the backbone · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C07H21/02

  with ribosyl as saccharide radical · CPC title